Literature DB >> 7947885

Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy.

V Jeevanandam1, B Todd, T Regillo, S Hellman, C Eldridge, J McClurken.   

Abstract

Triiodothyronine deficiency after brain death can result in progressive deterioration of cardiac function in potential organ donors. We report on the use of triiodothyronine replacement in improving myocardial function, allowing the use of donor hearts that might have been considered unsuitable for transplantation. From July to September 1992, of 24 organ procurements and transplantations, six donors were receiving high doses of inotropes with elevated left-sided filling pressures. Donor characteristics were as follows: five were male donors and one was a female donor, with mean age 16.50 +/- 7.50 years (8 to 30 years), mean weight 49.17 +/- 13.64 kg (25 to 63 kg), average time from clinical brain death to procurement 94.50 +/- 73.53 hours (49 to 240 hours), and two donors had arrest periods of up to 10 minutes. Despite large inotrope infusions, echocardiograms showed depressed left ventricular function (mean ejection fraction 39.17 +/- 5.85) and hemodynamic instability was present with elevated ventricular filling pressures. Triiodothyronine replacement (maximal dose 0.6 microgram/kg) was initiated an average of 139.17 +/- 32.00 minutes (115 to 185 minutes) before procurement. At the time of procurement, ventricular filling pressures were lower, hemodynamic condition stabilized, and pressor requirements decreased. Hearts were preserved in University of Wisconsin solution with a mean ischemic time of 188.83 +/- 36.86 minutes (149 to 237 minutes).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947885

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

Review 1.  How to increase the utilization of donor hearts?

Authors:  Maya Guglin
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

2.  Intensive Care Society of Ireland - Guidelines for management of the potential organ donor (2018-2nd edition).

Authors:  Ian Conrick-Martin; Alan Gaffney; Rory Dwyer; Colman O'Loughlin; Frances Colreavy
Journal:  Ir J Med Sci       Date:  2019-03-05       Impact factor: 1.568

Review 3.  Heart transplantation: approaching a new century.

Authors:  B Radovancević; O H Frazier
Journal:  Tex Heart Inst J       Date:  1999

4.  Survival of verapamil-poisoned rats treated with triiodothyronine.

Authors:  Michael J Lynch; Kenneth D Katz; Clifton W Callaway; Eric S Logue
Journal:  J Med Toxicol       Date:  2010-06

5.  Thyroid hormone use during cardiac transplant organ procurement.

Authors:  Lauren B Cooper; Carmelo A Milano; Melissa Williams; Wendy Swafford; Donna Croezen; Adrian B Van Bakel; Joseph G Rogers; Chetan B Patel
Journal:  Clin Transplant       Date:  2016-12       Impact factor: 2.863

6.  Tri-iodothyronine supplement protects gut barrier in septic rats.

Authors:  Zhi-Li Yang; Lian-Yue Yang; Geng-Wen Huang; He-Li Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats.

Authors:  Yue-Feng Chen; Satoru Kobayashi; Jinghai Chen; Rebecca A Redetzke; Suleman Said; Qiangrong Liang; A Martin Gerdes
Journal:  J Mol Cell Cardiol       Date:  2007-10-26       Impact factor: 5.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.